NCT04619628View on ClinicalTrials.gov

Safety and Immunogenicity of COVI-VAC, a Live Attenuated Vaccine Against COVID-19

PHASE1CompletedINTERVENTIONAL

Enrollment

48

Participants

Timeline

Start Date

December 11, 2020

Primary Completion Date

June 26, 2021

Study Completion Date

May 30, 2022

Conditions

COVID-19

Interventions

BIOLOGICAL

COVI-VAC

intranasal, live attenuated vaccine against SARS-CoV-2

OTHER

Placebo

normal saline

Trial Locations (1)

E1 2AX

hVIVO, London

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Codagenix, Inc

INDUSTRY